Lead Product(s): SPL84-23
Therapeutic Area: Genetic Disease Product Name: SPL84-23
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Biotel Limited
Deal Size: $28.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 13, 2021
Proceeds will be used to advance the Company’s pipeline, including its lead Anti Sense Oligonucleotide product, SPL84-23. SPL84-23 to treat the 3849+10kb C->T CFTR mutation, that has showed ability to completely restore CFTR channel function in patient-derived cell cultures.